NXI Therapeutics Expands Management Team and Board Ahead of Next Growth Stage
- Experienced life sciences executive Dr Ruben Herrendorff appointed as CEO
- Serial biotech entrepreneur Dr Ulf Grawunder appointed as Board member
- Targeted therapy aims to treat autoimmune disease whilst avoiding serious, long-term complications of the current non-selective immunosuppression
30 November 2022, Basel, Switzerland – NXI Therapeutics[1], the specialist biotech developing next generation immunosuppressive drugs for autoimmune diseases and organ transplantation, today announces that it has appointed Dr Ruben Herrendorff as its new CEO to drive the next stage of its development. Ruben was previously co-founder and CEO of Polyneuron Pharmaceuticals AG, a blue-chip VC-backed biotech developing a new antigen-specific technology platform to tackle antibody-mediated autoimmune diseases.
[1] NXI Therapeutics was previously known as NextImmune
